NASDAQ:DYN - Dyne Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.25
  • Forecasted Upside: 112.07 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$16.15
▼ -0.13 (-0.80%)

This chart shows the closing price for DYN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dyne Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DYN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DYN

Analyst Price Target is $34.25
▲ +112.07% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $34.25, with a high forecast of $47.00 and a low forecast of $27.00. The average price target represents a 112.07% upside from the last price of $16.15.

This chart shows the closing price for DYN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Dyne Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2021JonestradingInitiated CoverageBuyLow
10/12/2020JPMorgan Chase & Co.Initiated CoverageOverweight$27.00N/A
10/12/2020Stifel NicolausInitiated CoverageBuy$29.00N/A
10/12/2020Piper SandlerInitiated CoverageOverweight$34.00N/A
10/12/2020Jefferies Financial GroupInitiated CoverageBuy$47.00N/A
4/10/2018GuggenheimReiterated RatingBuyLow
3/6/2018SunTrust BanksReiterated RatingHold$14.00Low
1/22/2018SunTrust BanksSet Price TargetHold$13.00Low
11/2/2017Royal Bank of CanadaReiterated RatingHold$12.10N/A
10/31/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$13.00N/A
10/30/2017CitigroupSet Price TargetBuy$12.00N/A
10/27/2017SunTrust BanksDowngradeBuy ➝ HoldN/A
10/26/2017Morgan StanleySet Price TargetBuy$15.00N/A
10/24/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$11.00N/A
10/17/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellN/A
10/13/2017SunTrust BanksReiterated RatingBuyN/A
10/10/2017Royal Bank of CanadaReiterated RatingHold$8.00N/A
9/4/2017Royal Bank of CanadaReiterated RatingHold$8.00High
8/21/2017GuggenheimReiterated RatingBuy$14.00 ➝ $18.00High
8/7/2017Deutsche Bank AktiengesellschaftLower Price TargetHold$11.00 ➝ $10.00Low
7/25/2017BarclaysReiterated RatingBuy$13.00Low
4/26/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$6.00 ➝ $7.00High
3/15/2017Royal Bank of CanadaReiterated RatingHold$8.00High
2/21/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$7.01 ➝ $10.00N/A
2/9/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell$8.00 ➝ $6.00N/A
1/20/2017BarclaysBoost Price TargetBuy$13.00 ➝ $14.00N/A
1/18/2017UBS GroupDowngradeNeutral ➝ Sell$8.00 ➝ $7.00N/A
1/4/2017Royal Bank of CanadaReiterated RatingHold$9.00N/A
12/20/2016Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$7.01 ➝ $8.60N/A
10/20/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$22.00 ➝ $15.00N/A
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/18/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/17/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/16/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Dyne Therapeutics logo
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $16.15
Low: $16.05
High: $16.47

50 Day Range

MA: $17.73
Low: $15.60
High: $21.01

52 Week Range

Now: $16.15
Low: $13.50
High: $32.31

Volume

797 shs

Average Volume

319,975 shs

Market Capitalization

$828.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dyne Therapeutics?

The following sell-side analysts have issued research reports on Dyne Therapeutics in the last twelve months: Jefferies Financial Group Inc., Jonestrading, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for DYN.

What is the current price target for Dyne Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Dyne Therapeutics in the last year. Their average twelve-month price target is $34.25, suggesting a possible upside of 110.4%. Jefferies Financial Group Inc. has the highest price target set, predicting DYN will reach $47.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $27.00 for Dyne Therapeutics in the next year.
View the latest price targets for DYN.

What is the current consensus analyst rating for Dyne Therapeutics?

Dyne Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DYN will outperform the market and that investors should add to their positions of Dyne Therapeutics.
View the latest ratings for DYN.

What other companies compete with Dyne Therapeutics?

How do I contact Dyne Therapeutics' investor relations team?

The company's listed phone number is 781-786-8230 and its investor relations email address is [email protected] The official website for Dyne Therapeutics is www.dyne-tx.com.